AC Immune SA ACIU
NASDAQ
| 06/30/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -86.42% | -89.02% | 91.38% | 95.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -86.42% | -89.02% | 91.38% | 95.15% |
| Cost of Revenue | -- | -4.61% | 4.08% | 8.88% | 13.02% |
| Gross Profit | -- | -60.67% | -197.12% | 20.30% | 16.54% |
| SG&A Expenses | -- | -1.15% | -4.99% | -3.56% | 3.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 27.33% | 92.40% | 93.54% | 93.64% |
| Total Operating Expenses | -- | -3.82% | 2.67% | 7.25% | 12.48% |
| Operating Income | -- | -40.35% | -105.81% | 14.48% | 9.31% |
| Income Before Tax | -- | -47.97% | -89.86% | 14.13% | 5.99% |
| Income Tax Expenses | -- | -- | 209.09% | -24.44% | -56.41% |
| Earnings from Continuing Operations | -- | -47.96% | -89.86% | 14.13% | 5.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -47.96% | -89.86% | 14.13% | 5.99% |
| EBIT | -- | -40.35% | -105.81% | 14.48% | 9.31% |
| EBITDA | -- | -41.56% | -110.62% | 14.67% | 9.27% |
| EPS Basic | -- | -46.90% | -85.32% | 19.42% | 16.10% |
| Normalized Basic EPS | -- | -12.11% | -41.50% | 19.42% | 16.09% |
| EPS Diluted | -- | -44.66% | -83.61% | 18.34% | 14.99% |
| Normalized Diluted EPS | -- | -11.99% | -41.30% | 19.33% | 16.00% |
| Average Basic Shares Outstanding | -- | 0.62% | 3.79% | 8.23% | 12.47% |
| Average Diluted Shares Outstanding | -- | 0.36% | 3.52% | 8.50% | 12.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |